Capricor Therapeutics, Inc. (CAPR)
AI stock analysis · as of Aug 18, 2026
Loading microstructure…
Capricor Therapeutics (CAPR) is a clinical-stage biotech whose value is almost entirely tied to Deramiocel, an allogeneic cell therapy for Duchenne Muscular Dystrophy with a PDUFA date of August 22, 2026. With $288M cash against ~$80M annual burn, no product revenue, and a $433M market cap, the investment question is binary: does the resubmitted BLA (backed by HOPE-3 primary endpoint hit and positive Lancet data) get across the FDA finish line after the prior AdCom setback, unlocking an $80M milestone plus 30-50% U.S. revenue share via Nippon Shinyaku — or does a second CRL crater the equity?
valuationFairly priced as a probability-weighted binary — at $433M market cap and 1.54x P/B, the stock trades below approval-case value but above CRL-case value; PEG of 0.38 and $28 street high suggest deep undervaluation if Deramiocel approves, but negative FCF yield of -21% and no revenue mean traditional multiples are moot until FDA decides.
This analysis is from Aug 18, 2026. Want the latest on CAPR, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · HOPE-3 Phase 3 hit primary endpoint (PUL v2.0, 54% slowing, p=0.029) and key cardiac secondary (LVEF, 91% slowing, p=0.041), materially strengthening the resubmitted BLA
- · Well-capitalized for the binary: $288M cash vs $14.5M debt and ~$82M annual FCF burn provides runway through the Aug 2026 PDUFA and beyond
- · Approval unlocks an immediate $80M milestone from Nippon Shinyaku plus 30-50% U.S. revenue share, with additional ~$89M Japan milestones and a pending European deal worth $20M upfront + up to $715M
- · Stock is ~82% below the 52-week high ($40.37 vs $7.45); analyst target mean of $10.50 implies ~40% upside, and the high case of $28 reflects credible approval-case value
- · Institutional ownership at 71% suggests smart-money conviction despite the AdCom setback; PEG of 0.38 signals cheapness relative to potential ramp
- · Elevated short interest (30.5% of float, 3.28 days-to-cover) creates meaningful squeeze potential on positive FDA signals or a European deal signing
Bear case
- · Existential binary risk: a second CRL at the Aug 22, 2026 PDUFA would likely be company-threatening given no other approved products and no product revenue
- · Consensus is deteriorating — 4 analyst downgrades vs 1 upgrade in the last 90 days, with Jones Trading downgrading most recently (July 2026)
- · Securities fraud class-action lawsuit (Sept 2026 deadline) creates legal overhang and potential settlement/dilution risk
- · European Nippon Shinyaku definitive agreement has been repeatedly extended and remains unsigned; failure forfeits $20M upfront and up to $715M in milestones
- · Heavy partner concentration — Nippon Shinyaku holds exclusive U.S. and Japan distribution rights, limiting Capricor's commercial control and economics
- · Debt-to-equity of 36.98 and ROE of -73.7% reflect a fragile balance sheet structure; the CSMC manufacturing lease not renewing past mid-2026 concentrates supply risk on the single San Diego facility
- · StealthX Phase 1 showed limited neutralizing antibody response, undermining the platform-optionality story beyond Deramiocel
Catalysts
- · FDA PDUFA decision on Deramiocel by August 22, 2026 — the dominant catalyst
- · European definitive agreement signing with Nippon Shinyaku by April 1, 2026 deadline ($20M upfront + up to $715M)
- · StealthX Phase 1 final results in Q2 2026; positive readout could trigger NIH-funded Phase 2
- · Q3 2026 earnings on November 10, 2026 — likely post-PDUFA, will contextualize path forward
- · Potential short squeeze on positive FDA interim guidance/AdCom signals given 30.5% short float and 3.28 days-to-cover
- · Any FDA labeling/manufacturing inspection updates ahead of PDUFA
Key risks
- · Second CRL at PDUFA — highest-probability path to permanent capital impairment
- · Dilution risk: recent December 2025 offering and active ATM signal ongoing equity financing need if approval slips
- · Manufacturing/CMC concerns re-emerging as an FDA holdup, especially with CSMC lease exit
- · Failure to close European deal by April 1, 2026, removing a material milestone stream
- · Class-action litigation escalating into a material settlement
- · Nippon Shinyaku partnership renegotiation/termination risk given concentration
What to watch
- · August 22, 2026 PDUFA decision — the single dominant event
- · April 1, 2026 European Nippon Shinyaku deal deadline
- · Q2 2026 StealthX Phase 1 readout
- · November 10, 2026 earnings — post-PDUFA update on commercial ramp or contingency plan
- · Any FDA advisory committee re-convening or Type A/B meeting disclosures
- · Short interest and days-to-cover trend into PDUFA — squeeze setup on positive interim news
- · Key technical levels: 52-week low of $2.96 (bear floor) and $10.50 consensus (base resistance)
Key metrics
Price target rationale
Base case $9.50 blends ~40% probability of approval (implying ~$22 fair value on peak U.S. sales share + milestones) with ~60% probability of CRL/delay (implying ~$2-3 cash-value floor). Bull case $26 aligns with the $28 street high on clean approval, milestone receipt, and European deal closing. Bear case $2 reflects a second CRL scenario where value collapses toward net cash minus burn and litigation exposure.
On Wall Street's view (mixed): The $10.50 consensus mean (~40% upside) reasonably reflects a probability-weighted binary, but the wide $2-$28 target range and 4:1 downgrade-to-upgrade ratio in the last 90 days show analysts themselves are divided; we agree the risk/reward is asymmetric but think the mean under-prices the range of outcomes rather than being definitively right or wrong.
Latest filing (10-K)
Capricor is a binary-event biotech riding a single asset: Deramiocel's FDA approval decision by August 22, 2026 would trigger an $80M milestone and unlock a rare-disease franchise, but a second rejection would be existential for a company with no product revenue.
Capricor Therapeutics is a clinical-stage biotechnology company developing cell and exosome-based therapeutics for rare diseases, primarily Duchenne muscular dystrophy (DMD). Its lead asset, Deramiocel (cardiosphere-derived cells), has a BLA under FDA review with a PDUFA date of August 22, 2026, following a CRL in July 2025 and subsequent Class 2 resubmission. The company has no approved products and generates no product revenue; it funds operations through equity raises and milestone payments from its exclusive distribution partner, Nippon Shinyaku Co., Ltd.
What the news says · bullish
The dominant storyline for CAPR is a volatile, high-stakes regulatory journey for its lead asset deramiocel in Duchenne Muscular Dystrophy (DMD). After an AdCom setback that caused a sharp fair value cut and an 86% analyst price target slash, the stock has staged a notable recovery driven by positive Lancet data, an analyst upgrade, and news that the FDA is keeping a regulatory approval path alive. However, a securities fraud class-action lawsuit with a September 2026 deadline adds meaningful legal overhang that tempers the bullish momentum. The stock appears to be a high-risk, high-reward binary play on FDA outcomes, with some analysts suggesting it may be significantly undervalued if deramiocel succeeds.
This analysis is from Aug 18, 2026. Markets move. Get the current read on CAPR and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.